BOLT | Bolt Biotherapeutics, Inc.

Index- P/E- EPS (ttm)-2.17 Insider Own9.80% Shs Outstand37.68M Perf Week-5.26%
Market Cap61.27M Forward P/E- EPS next Y-1.64 Insider Trans0.00% Shs Float35.19M Perf Month0.62%
Income-81.40M PEG- EPS next Q-0.49 Inst Own68.00% Short Float / Ratio4.25% / 6.56 Perf Quarter0.00%
Sales6.70M P/S9.14 EPS this Y10.50% Inst Trans-0.17% Short Interest1.50M Perf Half Y11.72%
Book/sh4.18 P/B0.39 EPS next Y12.40% ROA-34.60% Target Price5.17 Perf Year-20.98%
Cash/sh3.34 P/C0.49 EPS next 5Y- ROE-44.90% 52W Range1.18 - 2.72 Perf YTD24.62%
Dividend- P/FCF- EPS past 5Y- ROI-52.70% 52W High-40.44% Beta-
Dividend %- Quick Ratio8.10 Sales past 5Y- Gross Margin- 52W Low37.29% ATR0.12
Employees94 Current Ratio8.10 Sales Q/Q125.00% Oper. Margin- RSI (14)42.52 Volatility6.72% 6.82%
OptionableNo Debt/Eq0.00 EPS Q/Q29.30% Profit Margin- Rel Volume0.28 Prev Close1.68
ShortableYes LT Debt/Eq0.00 EarningsMar 29 AMC Payout- Avg Volume228.18K Price1.62
Recom1.70 SMA20-8.99% SMA501.54% SMA2006.46% Volume64,554 Change-3.57%
Date Action Analyst Rating Change Price Target Change
Jan-06-22Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-02-21Initiated SVB Leerink Outperform $36
Mar-02-21Initiated Stifel Buy $40
Mar-02-21Initiated Morgan Stanley Overweight $45
Mar-02-21Initiated Guggenheim Buy $42
May-30-23 08:00AM
May-25-23 05:05PM
May-11-23 04:05PM
Apr-26-23 10:00AM
Apr-11-23 07:41AM
01:16PM Loading…
Mar-30-23 01:16PM
Mar-29-23 04:15PM
04:05PM
Mar-14-23 04:30PM
Feb-28-23 08:00AM
Feb-01-23 08:00AM
Jan-04-23 09:31AM
Dec-14-22 04:43PM
Nov-10-22 04:05PM
Nov-07-22 08:00AM
07:20AM Loading…
Nov-02-22 07:20AM
Nov-01-22 10:01AM
08:00AM
Sep-09-22 12:08PM
Aug-31-22 07:30AM
Aug-25-22 12:23PM
12:02PM
Aug-10-22 04:05PM
Jul-22-22 08:44AM
Jun-10-22 07:21AM
May-27-22 08:00AM
May-26-22 06:52AM
May-13-22 08:28AM
May-12-22 04:05PM
May-11-22 07:32AM
08:00AM Loading…
Apr-07-22 08:00AM
Mar-30-22 04:05PM
Mar-08-22 04:30PM
Feb-12-22 06:30AM
Feb-02-22 08:00AM
Jan-27-22 01:43PM
Jan-06-22 08:00AM
Dec-17-21 06:14AM
Dec-16-21 08:00AM
Dec-06-21 04:29PM
09:23AM
06:00AM
Dec-02-21 06:00AM
Nov-19-21 08:00AM
Nov-12-21 07:00AM
Nov-09-21 04:05AM
Nov-08-21 08:00AM
Nov-03-21 08:00AM
Oct-01-21 08:00AM
Sep-08-21 07:30AM
Sep-02-21 08:00AM
Aug-27-21 05:55AM
Aug-26-21 04:05PM
Aug-16-21 06:26AM
Aug-12-21 04:05PM
Aug-02-21 04:32PM
Jul-20-21 12:42AM
Jun-22-21 08:16PM
08:00PM
06:20PM
05:33PM
03:41PM
02:10PM
01:03PM
12:30PM
12:11PM
12:00PM
11:33AM
11:24AM
11:00AM
09:24AM
08:00AM
05:22AM
02:00AM
Jun-21-21 10:43PM
08:00PM
07:36PM
05:43PM
04:12PM
02:25PM
01:40PM
01:30PM
11:30AM
11:23AM
11:00AM
10:25AM
09:23AM
05:51AM
Jun-20-21 03:25PM
03:00PM
12:37PM
03:43AM
Jun-19-21 08:01PM
05:16PM
Jun-18-21 10:50PM
08:25PM
06:45PM
05:57PM
12:00PM
11:30AM
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Holdings A/S10% OwnerJul 13Sale2.00800,0001,600,0003,703,991Jul 15 04:16 PM